OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Washington -- Oral tazarotene (Tazorac; Allergan Inc., Irvine, Calif.,) gives patients with plaque psoriasis significant improvements that continue after treatment stops, according to a poster study presented at this year's annual meeting of the American Academy of Dermatology. The blinded, placebo-controlled, multicenter study of about 700 patients shows that oral tazarotene delivers several advantages over existing treatment alternatives.
Related Content:
News